<DOC>
	<DOC>NCT02663102</DOC>
	<brief_summary>The purpose of this study is collect safety information on the use of Fluarix Tetra according to the approved PI, over a period of 6 years from children (over 3 years of age) and adults in Korea.</brief_summary>
	<brief_title>Evaluation of Safety of GlaxoSmithKline (GSK) Vaccines' Quadrivalent Seasonal Influenza Vaccine, Fluarix Tetra When Administered According to the Approved Prescribing Information (PI) in Korea.</brief_title>
	<detailed_description>Adults and previously vaccinated children aged â‰¥36 months, a single dose of Fluarix Tetra will be administered. To previously unvaccinated children aged 36 months to &lt;9 years, two doses will be administered with a second dose at least 4 weeks apart from the first one as per the local PI in Korea. Fluarix Tetra may be administered to pregnant women/lactating women as per PI, if there is a clear need. Pregnancy outcome (whether full-term or premature, information on the status of the mother and child) in vaccinated pregnant subjects will be followed-up at 6-8 weeks after delivery, if possible.</detailed_description>
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Tetracycline</mesh_term>
	<criteria>Male or female subjects who were vaccinated with Fluarix Tetra or eligible to receive Fluarix Tetra according to the locally approved PI. Signed informed consent as Informed Consent Form (ICF)/Informed Assent Form (IAF) obtained from the subject/subject's parent(s)/Legally acceptable Representative(s) [LAR(s)]. Those who are not eligible for vaccination with Fluarix Tetra according to the local PI. Hypersensitivity reaction to Fluarix Tetra. History of hypersensitivity reaction to Influenza vaccine. History of GuillainBarre syndrome or other nervous system abnormalities to Influenza vaccine within 6 weeks postvaccination. Those who are not eligible for vaccination with Fluarix Tetra according to the medical judgement of physician.</criteria>
	<gender>All</gender>
	<minimum_age>36 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Safety</keyword>
	<keyword>Post-marketing</keyword>
	<keyword>Korea</keyword>
	<keyword>Drug utilization study</keyword>
	<keyword>Fluarix Tetra</keyword>
</DOC>